OPEN-LABEL, PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND PRELIMINARY CLINICAL RESPONSE TO THE USE OF ALLOGENEIC BONE MARROW MESENCHYMAL STEM CELLS IN CHILDREN AND ADOLESCENTS WITH X-LINKED ADRENOLEUKODYSTROPHY CEREBRAL FORM.
Adrenoleukodystrophy (ALD) is a rare inherited condition that can severely affect the brain and nervous system in boys and young men. The cerebral form causes inflammation that damages the protective layer around brain nerves. This early safety trial is testing an experimental therapy using special cells called mesenchymal stem cells, taken from healthy donor bone marrow. Doctors hope these cells might calm inflammation and protect nerve tissue. Because this is a Phase I trial—one of the first times this therapy is being tested in humans—the main goal is safety. Doctors will closely check how the body handles the treatment during the first month and look for any unwanted side effects. The study aims to find out if this approach is safe enough to test in larger groups in the future.
At a glance
What is this study about?
Adrenoleukodystrophy (often called ALD) is a rare genetic condition that mainly affects males. In its cerebral form, harmful fatty substances build up in the body and trigger inflammation in the brain. Over time, this inflammation strips away myelin, the protective coating around nerve cells. Without this coating, nerves struggle to send messages, which can lead to severe difficulties with movement, learning, vision, and speech.
In this study, scientists are exploring a new approach using mesenchymal stem cells. These are natural repair cells taken from the bone marrow of healthy donors. Scientists believe these cells may help reduce dangerous inflammation and support the brain's natural healing environment. The cells are prepared carefully in a laboratory and given through a drip.
Because this is a Phase I trial, the main aim is not to cure the condition straight away, but to find out if the treatment is safe to use. Doctors want to see how young patients tolerate the infusion and monitor them closely for any negative reactions. If this early step proves safe, it may pave the way for better treatments for families facing this challenging condition in the future.
Key takeaways
- This is a Phase I trial checking the safety of a donor stem cell infusion for cerebral ALD.
- The study is only open to male patients diagnosed with the cerebral form of the disease.
- The treatment aims to lower harmful inflammation in the brain.
- Safety will be monitored very closely, especially during the first 28 days after the drip.
- Taking part is voluntary and does not guarantee a direct health benefit.
Who may be eligible?
This trial is designed specifically for males who have been diagnosed with the cerebral form of X-linked adrenoleukodystrophy. Because the gene fault is carried on the X chromosome and the brain-affecting form occurs almost entirely in males, females are not eligible for this study.
Participants must have active signs of the cerebral form of the disease. The study team will need to review detailed medical records, including brain scans such as MRIs, to confirm whether the disease is at the right stage for this treatment.
Patients who are already receiving certain other advanced treatments, or who have other severe health conditions that could make the infusion unsafe, may not be able to take part. The trial team will carry out a thorough health check before anyone is accepted into the study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- The patient is male.
- The patient has a confirmed diagnosis of X-linked adrenoleukodystrophy (ALD).
- There is evidence of the cerebral form affecting the brain.
- The family is able to attend hospital appointments and regular follow-up visits.
- The patient is not currently in another conflicting clinical trial.
What does participation involve?
If a child or young person joins this study, they will first have a series of baseline checks, including blood tests, physical examinations, and brain scans (MRIs). The treatment itself is given as a single infusion into a vein through a drip. The donor stem cells are carefully thawed and prepared just before the injection.
After receiving the cells, the patient will be observed very closely in hospital to make sure there are no immediate allergic reactions or complications. Over the following 28 days, there will be frequent follow-up visits so doctors can check for any side effects, take further blood samples, and monitor overall health.
Follow-up visits and scans will continue over several months to evaluate how the body responds to the cells. In total, being part of the study will require multiple hospital appointments, regular communication with the medical team, and ongoing monitoring for at least a year.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What are mesenchymal stem cells?
They are specialised cells found in places like bone marrow that can calm down the immune system, lower inflammation, and help repair tissues.
Is this trial open to girls?
No. The cerebral form of X-linked ALD affects males, so this study is only open to boys and young men.
Will taking part cure ALD?
No, this is a safety study. Doctors are trying to find out if the treatment is safe and tolerable, not offering a proven cure.
Where do the stem cells come from?
The cells come from healthy bone marrow donors and are thoroughly tested, cleaned, and prepared in a specialist laboratory.
Can we stop taking part if we change our minds?
Yes. You can withdraw your child from the study at any time, and it will not change the standard medical care they receive.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.